Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. The company has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. The company also offers VivaGel BV and VivaGel Condom products.
Follow-Up Questions
Starpharma Holdings Ltd 'in CEO'su kimdir?
Ms. Cheryl Maley 2024 'den beri şirketle birlikte olan Starpharma Holdings Ltd 'in Chief Executive Officer 'ıdır.
SPHRY hissesinin fiyat performansı nasıl?
SPHRY 'in mevcut fiyatı $0.8448 'dir, son işlem günde 0% decreased etti.
Starpharma Holdings Ltd için ana iş temaları veya sektörler nelerdir?
Starpharma Holdings Ltd Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Starpharma Holdings Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 3 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
